anagrelide: Clinical Trials

8 trials of anagrelide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 active not recruiting, 1 terminated. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 5, Active not recruiting 2, Terminated 1
Phase 21Terminated 1

Follow anagrelide: new trials by email Literature Review of anagrelide trials Research Report on anagrelide

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia
Phase 3Active not recruitingMerck Sharp & Dohme LLC3402023-12-312026-10-02
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia
Phase 3Active not recruitingPharmaEssentia1742020-08-252026-07-22
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia
Phase 2 / Phase 3TerminatedFrench Innovative Leukemia Organisation132017-01-032021-06-29
Anagrelide Retard in Essential Thrombocythemia
Anagrelide retard, Thromboreductin - Essential Thrombocythemia
Phase 3CompletedAOP Orphan Pharmaceuticals AG1062014-02-012015-07-29
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
ruxolitinib tablets, Best Available Therapy (BAT) - Polycythemia Vera
Phase 3CompletedIncyte Corporation2222010-10-272019-03-06
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
SPD422 (anagrelide hydrochloride) - Essential Thrombocythemia (ET)
Phase 3CompletedShire412010-10-272021-06-09
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Anagrelide Hydrochloride - Essential Thrombocythemia (ET)
Phase 3CompletedShire532010-10-272021-06-09
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Anagrelide, Hydroxyurea - Essential Thrombocythaemia
Phase 3CompletedAOP Orphan Pharmaceuticals AG2002-09-012010-10-06

Conditions studied

Thrombocythemia, Essential (7)  ·  Myeloproliferative Disorders (2)  ·  Polycythemia Vera (1)

Sponsors

AOP Orphan Pharmaceuticals AG (2)  ·  Shire (2)  ·  French Innovative Leukemia Organisation (1)  ·  Incyte Corporation (1)  ·  Merck Sharp & Dohme LLC (1)  ·  PharmaEssentia (1)

Countries

Japan (5)  ·  France (4)  ·  Canada (3)  ·  China (3)  ·  Germany (3)  ·  Hungary (3)  ·  Italy (3)  ·  Poland (3)  ·  South Korea (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Hong Kong (2)

Top investigators

Craig Zimmerman, PhD (1)  ·  Heinz Gisslinger, Prof., MD (1)  ·  Mark Jones, MD (1)  ·  Srdan Verstovsek, MD,PhD (1)  ·  Toshiaki Sato, MD/PhD (1)

Results publications

PMID 23315161, PMID 25160063, PMID 25629741, PMID 27102499, PMID 28193568, PMID 29396713, PMID 30121892, PMID 31982039, PMID 35924546, PMID 41193116, PMID 41890273

NIH funding

2023 (1)